GARM Clinic, based in Roatán, has added Klotho to its portfolio of non-permanent gene therapies, positioning itself at the forefront of high-end healthspan medicine. This development highlights a growing trend where specialized clinics are offering advanced therapies that appeal to early adopters, including biohackers and health enthusiasts, seeking tangible improvements in performance and longevity.

Klotho has garnered attention in the longevity field for its potential to enhance lifespan and healthspan by supporting mitochondrial function, organ health, and cognitive clarity. As natural Klotho production declines with age, its therapeutic application could help mitigate some age-related declines in resilience and metabolic efficiency. GARM’s approach, which also includes Follistatin and VEGF, reflects a shift in focus from merely extending lifespan to enhancing functional health, addressing key aging concerns such as muscle maintenance, blood flow, and inflammation.

The introduction of Klotho at GARM underscores a broader movement within longevity medicine toward accessible, innovative therapies that prioritize healthspan. As the market matures, the implications for clinical practice and patient accessibility will be critical to monitor, particularly as elite offerings may pave the way for wider acceptance and integration of longevity interventions in mainstream healthcare.

Source: longevity.technology